Is gonadorelin FDA-approved, and what does the research show?

What is gonadorelin?

Gonadorelin is the drug name for gonadotropin-releasing hormone, or GnRH ¹. FDA's records carry it as two salts, gonadorelin hydrochloride in Factrel and gonadorelin acetate in the Lutrepulse Kit ², ³. The body releases its own GnRH in pulses ⁵. GnRH tells the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, LH and FSH, which in men raise testosterone and support sperm production ⁵, ⁶.

Congenital hypogonadotropic hypogonadism is a rare disorder caused by GnRH deficiency or resistance, in which puberty does not start or stops ⁵. Gonadorelin has been studied as a replacement for that signal ⁵, ⁶. It has also been studied as a stimulation test, to measure how the pituitary responds ⁸. If you are asking about gonadorelin given alongside testosterone therapy, to keep the testes working, that is a different use from the studies on this page.

Is gonadorelin FDA-approved?

Compounded gonadorelin is not FDA-approved. Two gonadorelin products were approved in the past. Factrel, gonadorelin hydrochloride, was approved on September 30, 1982 ². The Lutrepulse Kit, gonadorelin acetate, was approved on October 10, 1989 and is marked "Orphan" in Drugs@FDA ³.

Drugs@FDA, FDA's record of approved drug products, lists every strength of both as "Discontinued", and no label for either is available on the site ², ³. The openFDA copy of that record holds no other gonadorelin application, as of November 9, 2026, its data date ⁴.

FDA also keeps two lists of substances nominated for compounding, under sections 503A and 503B of the law. The 503A list, updated May 14, 2026, does not name gonadorelin ⁹. The 503B list, which covers outsourcing facilities, was updated March 21, 2025 ¹⁰. It names "Gonadorelin Acetate" in Category 1, "Bulk Drug Substances Under Evaluation," and marks it as a component of an FDA-approved drug ¹⁰. Gonadorelin hydrochloride is also an approved animal drug, used in dairy cows to time artificial insemination; that approval is for animals, not people ¹¹.

See the FDA status of every peptide, updated weekly.

How does gonadorelin work?

Gonadorelin replaces the GnRH signal in people with hypogonadotropic hypogonadism ⁵. Given in pulses by a portable pump under the skin, it mimics the body's own pulsed release and prompts the pituitary to release LH and FSH ⁵. In men with congenital hypogonadotropic hypogonadism, those hormones then raise testosterone, enlarge the testes and can start sperm production ⁵, ⁶. In their discussion, the authors write, citing earlier work, that LH and FSH can return to normal in most men on pulsatile GnRH ⁵. They also note that GnRH receptors have been found on sperm-forming cells, so a direct effect on sperm is proposed, not shown ⁵.

What does the research show?

In men with congenital hypogonadotropic hypogonadism, pulsatile therapy has been compared with gonadotropin injections, hCG with or without hMG ⁵. A systematic review and meta-analysis published online July 14, 2020 pooled seven comparative studies, eight articles, with 420 men with congenital hypogonadotropic hypogonadism ⁵. None was randomized, four of the seven were retrospective, and in three the GnRH arm had fewer than ten men ⁵.

Men on pulsatile GnRH had larger testicular volume at the end of treatment ⁵. Sperm appeared about five months earlier, a weighted mean difference of 5.30 months, 95% confidence interval 1.67 to 8.93 ⁵. The share of men with sperm in their semen, the sperm concentration and the pregnancy rate did not differ significantly between the two treatments ⁵. Testosterone ran higher on gonadotropins, by 7.75 nmol/L on average ⁵. The authors call for "prospective, randomized studies with larger sample sizes" ⁵.

A 2002 report followed 11 men with idiopathic hypogonadotropic hypogonadism on long-term pulsatile GnRH under the skin; three had a history of undescended testes ⁶. Testicular volume and the levels of FSH, LH and testosterone rose ⁶. Sperm appeared in the semen of 9 of the 11, eight on GnRH alone and one after switching to hCG and hMG, and seven pregnancies followed ⁶. The authors judged that many men need a minimum of one to two years of treatment, and that undescended testes predicted a poorer result ⁶. The report describes one treated group, with no comparison arm ⁶.

In women, the Lutrepulse Kit's maker, Ferring, ran a randomized, double-blind, placebo-controlled Phase 3 trial of gonadorelin acetate by pump ⁷. It enrolled 39 women aged 18 to 40 with primary amenorrhea from hypogonadotropic hypogonadism, ran from April 2014 to February 2018, and posted results on March 3, 2021 ⁷. Across the two higher of three dose arms, 9 of 18 women ovulated against 0 of 10 on placebo (p = 0.012); in the lowest arm, 1 of 9 did ⁷. Clinical pregnancies followed in 7 of 19 women in the two higher arms and in none on placebo ⁷.

Testosterone injections can suppress sperm production ⁵. No published trial of gonadorelin given alongside testosterone therapy, to maintain testicular size or function, was found among the sources opened, as of November 9, 2026. The studies above enrolled people with hypogonadotropic hypogonadism ⁵, ⁶, ⁷; none tested gonadorelin in men taking testosterone. A narrative review published September 30, 2026, which searched for gonadorelin among the peptides used in sexual medicine, records it as formerly FDA-approved and "no longer manufactured" ¹². The same review describes peptide use in that field as often influenced by off-label prescribing and direct-to-consumer promotion, with limited long-term safety data ¹².

What are the side effects?

In the pooled studies of men, the adverse reactions reported were allergic reactions, breast development and acne ⁵. Overall rates were similar on pulsatile GnRH and on gonadotropins ⁵. The allergic reactions occurred mostly on GnRH, and the authors describe most of them as mild to moderate skin reactions ⁵. Breast development and acne were linked to the gonadotropin injections ⁵. The 2002 series of 11 men called the treatment "well-tolerated" ⁶.

In the 39-woman trial, no serious adverse event was recorded ⁷. Some adverse event was recorded in 12 of 28 women on gonadorelin and 4 of 11 on placebo, nearly every event in one or two women ⁷. Breast tenderness was reported in four women on gonadorelin and none on placebo, and one woman on gonadorelin had a hemorrhagic ovarian cyst ⁷.

FDA's labels for Factrel and the Lutrepulse Kit are not available on Drugs@FDA, so FDA's own safety wording is not quoted here ², ³. No safety data on compounded gonadorelin, or on gonadorelin given with testosterone therapy, was found among the sources opened, as of November 9, 2026.

In sport

WADA, the World Anti-Doping Agency, names "gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues" on its 2026 Prohibited List under S2.2.1, "Testosterone-stimulating peptides in males" ¹. Class S2 is prohibited at all times, in and out of competition ¹.

What JumpstartMD offers

JumpstartMD does not prescribe gonadorelin. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.